Assessment of Anti-Cytogenotoxic Effects of Quercetin in Animals Treated with Topotecan

Table 2

Frequency of MNPCE and mitotic activity (% PCE) in bone marrow of mice treated with quercetin and/or topotecan (TPT) or cyclophosphamide (mean ± SD).

Treatment groups; (mg/kg)	% MNPCE (mean ± SD)	% PCE; (mean ± SD)
Control	0.36 ± 0.11	48.8 ± 1.78
Quercetin (50)	0.32 ± 0.08	48.2 ± 2.15
Quercetin (100)	0.30 ± 0.10	48.4 ± 1.81
TPT (0.5)	1.68 ± 0.24**	41.6 ± 3.43*
Quercetin (50) + TPT (0.5)	0.96 ± 0.23^b	45.8 ± 2.77
Quercetin (100) + TPT (0.5)	0.58 ± 0.13^b	47.4 ± 2.40^b
TPT (1)	2.62 ± 0.54**	39.6 ± 2.19*
Quercetin (50) + TPT (1)	1.90 ± 0.48	44.0 ± 5.78
Quercetin (100) + TPT (1)	0.72 ± 0.14^b	47.6 ± 2.60^b
Cyclophosphamide 40	2.06 ± 0.43^#	42.2 ± 2.58^#

^∗𝑃<0.05 and ^∗∗𝑃<0.01 versus control (Kruskal-Wallis test followed by Dunn’s multiple comparisons test). ^b𝑃<0.01 versus the corresponding TPT alone; ^#𝑃<0.01 versus control (Mann-Whitney U test).